MARCHESINI, MATTEO
 Distribuzione geografica
Continente #
EU - Europa 390
NA - Nord America 375
AS - Asia 128
AF - Africa 3
Totale 896
Nazione #
US - Stati Uniti d'America 375
IT - Italia 148
CN - Cina 101
IE - Irlanda 97
SE - Svezia 55
AT - Austria 26
DE - Germania 20
SG - Singapore 20
FI - Finlandia 12
CZ - Repubblica Ceca 8
FR - Francia 8
IN - India 3
CI - Costa d'Avorio 2
ES - Italia 2
GB - Regno Unito 2
GR - Grecia 2
IL - Israele 2
NL - Olanda 2
PT - Portogallo 2
TR - Turchia 2
BE - Belgio 1
BG - Bulgaria 1
EG - Egitto 1
LU - Lussemburgo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
UA - Ucraina 1
Totale 896
Città #
Chandler 114
Dublin 97
Parma 45
Shanghai 38
Ashburn 37
Boardman 25
Vienna 24
Ann Arbor 21
Milan 15
Bremen 14
Princeton 14
Singapore 14
Beijing 13
Wilmington 11
New York 10
Bologna 9
Carpi 8
Dearborn 8
Brno 7
Nanjing 6
Des Moines 5
Helsinki 5
Kunming 5
Fairfield 4
Hebei 4
San Mateo 4
Changsha 3
Chicago 3
Hefei 3
Modena 3
Nanchang 3
Perugia 3
Rome 3
Rovereto 3
Shenyang 3
Woodbridge 3
Abidjan 2
Amsterdam 2
Athens 2
Chengdu 2
Cordovado 2
Cosenza 2
Falls Church 2
Fidenza 2
Houston 2
Izmir 2
Jiaxing 2
Jinan 2
Leytonstone 2
Los Angeles 2
Orzinuovi 2
Pescara 2
Pune 2
Reggio Emilia 2
Rho 2
Sassuolo 2
Seattle 2
Tianjin 2
Turin 2
Zhengzhou 2
Boretto 1
Bratislava 1
Cairo 1
Casoria 1
Catania 1
Cornaredo 1
Eboli 1
Esslingen am Neckar 1
Falkenstein 1
Frankfurt am Main 1
Fremont 1
Geislingen an der Steige 1
Genova 1
Ghent 1
Luxembourg 1
Male Hostice 1
Marseille 1
Mezzolombardo 1
Naples 1
Norwalk 1
Redmond 1
Rockville 1
Segrate 1
Sofia 1
Verona 1
Vignola 1
Viterbo 1
Totale 662
Nome #
Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia 111
Targeting oncogenic Notch signaling with SERCA inhibitors 105
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia 68
ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma 65
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 63
Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome 62
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia 53
ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA 48
Orthogonal Proteogenomic Approaches Identify the Druggable PA2G4-MYC Axis in 3q26 AML 46
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function 43
PAF promotes stemness and radioresistance of glioma stem cells 41
PML is required for telomere stability in non-neoplastic human cells 38
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer 36
Identification of the Atypical Protein Kinase WNK1 As a New Target in T-Cell Acute Lymphoblastic Leukemia 35
RNA processing: A new player of genomic instability in multiple myeloma 35
Down-regulation of EZH2 expression in myelodysplastic syndromes 28
A pool of peptides extracted from wheat bud chromatin inhibits tumor cell growth by causing defective DNA synthesis 28
SELECTIVE BLOCKADE OF ONCOGENIC NOTCH1 WITH THE NEW SERCA INHIBITOR CAD204520 11
Selective Blockade of Oncogenic NOTCH1 with the New SERCA Inhibitor CAD204520 in T-cell Acute Lymphoblastic Leukemia 7
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma 7
Targeting the Activating Mutations of NOTCH1 in T-Cell Lymphoblastic Leukemia with a New SERCA Inhibitor CAD204520 6
Totale 936
Categoria #
all - tutte 3.806
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.806


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202060 14 15 0 1 3 5 6 2 0 5 4 5
2020/202182 0 1 2 21 4 4 1 7 12 17 3 10
2021/202271 3 3 5 4 2 2 12 5 1 6 1 27
2022/2023404 22 43 19 38 50 44 14 25 118 4 23 4
2023/2024271 13 6 7 14 13 32 74 10 13 24 16 49
2024/20259 9 0 0 0 0 0 0 0 0 0 0 0
Totale 936